title: Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG).
abstract: METHODS
  From October, 1986 to July 1989, 35 consecutive patients with high- and intermediate-grade non-Hodgkin's lymphoma, relapsed or refractory to first-line-anthracycline-containing regimens, were treated with mitoxantrone alone or in combination chemotherapy (VeMP: Ve = VP-16, M = Mitoxantrone, P = Prednisolone).
  
  
  RESULTS
  In the first 15 patients, treated with Mitoxantrone alone, complete response (CR) and partial response (PR) each occurred in 4 patients, for a total response rate of 54%. In the following 20 patients, treated with the VeMP regimen, CR occurred in 10 patients (50%), PR in 1. The overall three-year survival was 27% in the first group and 40% in the second. Acute toxicity was generally mild. No patient developed cardiac symptoms or other toxicities requiring discontinuation of therapy. Myelosuppression was the most important side effect, being more remarkable for patients treated with VeMP regimen.
  
  
  CONCLUSIONS
  Mitoxantrone, alone or in combination chemotherapy, appears to be a drug with significant activity in aggressive non-Hodgkin's lymphomas.
authors.affiliation: Divisione di Ematologia I, Ospedale Civile, Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Santini
authors.forename: A
authors.initials: A
authors.lastname: Contu
authors.forename: A
authors.initials: A
authors.lastname: Porcellini
authors.forename: T
authors.initials: T
authors.lastname: Chisesi
authors.forename: P
authors.initials: P
authors.lastname: Coser
authors.forename: A M
authors.initials: AM
authors.lastname: Congiu
authors.forename: S
authors.initials: S
authors.lastname: Morandi
authors.forename: A
authors.initials: A
authors.lastname: Manna
authors.forename: G M
authors.initials: GM
authors.lastname: Schintu
authors.forename: R
authors.initials: R
authors.lastname: Quaini
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D008942:Mitoxantrone; D015122:Mercaptopurine